Atrás
Rango del Día
$50.48
$51.68
Rango de 52 Semanas
$38.39
$51.68
Volumen
19,975,306
Promedio 50D / 200D
$46.25
/
$43.05
Cierre Anterior
$50.58
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Communication Services (238 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 12.5 | 5.8 |
| P/B | 2.1 | 1.3 |
| ROE % | 16.9 | 9.3 |
| Net Margin % | 12.4 | 6.4 |
| Rev Growth 5Y % | 0.9 | 5.1 |
| D/E | 1.9 | 0.7 |
Precio Objetivo de Analistas
Hold
$50.14
-1.5%
Low: $44.00
High: $58.00
P/E Futuro
10.3
EPS Futuro
$4.91
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
140 B
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2030 |
$6.97
$6.78 – $7.16
|
150 B | 6 |
| FY2029 |
$6.04
$5.87 – $6.21
|
150 B | 6 |
| FY2028 |
$5.69
$5.16 – $6.12
|
150 B | 8 |
Insider Trading Activity
19 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 |
Villanueva Rodriguez Alfonso
EVP&Int.Group CEO-VZ Cons.&CTO
|
grant | 72 | $14.44 | $1,040 |
| Feb 26, 2026 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 7,223 | $13.95 | $100,761 |
| Jan 15, 2026 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 155 | $11.24 | $1,742 |
| Jan 15, 2026 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 175 | $11.24 | $1,967 |
| Dec 31, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 150 | $11.63 | $1,745 |
| Dec 4, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 147 | $11.78 | $1,732 |
| Nov 6, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 173 | $11.37 | $1,967 |
| Nov 6, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 152 | $11.37 | $1,728 |
| Oct 9, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 168 | $11.66 | $1,959 |
| Oct 9, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 148 | $11.66 | $1,726 |
| Sep 25, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 159 | $12.37 | $1,967 |
| Jul 31, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 161 | $12.20 | $1,964 |
| Jul 2, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 139 | $12.44 | $1,729 |
| Jun 18, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 165 | $11.89 | $1,962 |
| Jun 5, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 159 | $12.35 | $1,964 |
| May 22, 2025 |
Sampath Sowmyanarayan
EVP and Group CEO-VZ Consumer
|
grant | 159 | $12.31 | $1,957 |
| Apr 30, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
sell | 7,500 | $43.88 | $329,063 |
| Apr 23, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
sell | 5,000 | $42.49 | $212,425 |
| Mar 27, 2025 |
Malady Kyle
EVP and Group CEO-VZ Business
|
grant | 135 | $12.82 | $1,731 |
Puntos Clave
Revenue grew 0.85% annually over 5 years — modest growth
ROE of 16.86% — decent returns on equity
Generating 20.13B in free cash flow
P/E of 12.50 — trading at a low valuation
Cash machine — converts 117.19% of earnings into free cash flow
Crecimiento
Revenue Growth (5Y)
0.85%
Revenue (1Y)2.52%
Earnings (1Y)-1.90%
FCF Growth (3Y)3.72%
Calidad
Return on Equity
16.86%
ROIC7.19%
Net Margin12.43%
Op. Margin21.17%
Seguridad
Debt / Equity
1.92
Current Ratio0.91
Interest Coverage4.37
Valoración
P/E Ratio
12.50
P/B Ratio2.06
EV/EBITDA13.54
Dividend Yield0.07%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2.52% | Revenue Growth (3Y) | 1.56% |
| Earnings Growth (1Y) | -1.90% | Earnings Growth (3Y) | 21.60% |
| Revenue Growth (5Y) | 0.85% | Earnings Growth (5Y) | -6.07% |
| Profitability | |||
| Revenue (TTM) | 138.19B | Net Income (TTM) | 17.17B |
| ROE | 16.86% | ROA | 4.25% |
| Gross Margin | 45.64% | Operating Margin | 21.17% |
| Net Margin | 12.43% | Free Cash Flow (TTM) | 20.13B |
| ROIC | 7.19% | FCF Growth (3Y) | 3.72% |
| Safety | |||
| Debt / Equity | 1.92 | Current Ratio | 0.91 |
| Interest Coverage | 4.37 | Dividend Yield | 0.07% |
| Valuation | |||
| P/E Ratio | 12.50 | P/B Ratio | 2.06 |
| P/S Ratio | 1.55 | PEG Ratio | -4.62 |
| EV/EBITDA | 13.54 | Dividend Yield | 0.07% |
| Market Cap | 214.72B | Enterprise Value | 396.27B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 138.19B | 134.79B | 133.97B | 136.84B | 133.61B |
| Net Income | 17.17B | 17.51B | 11.61B | 21.26B | 22.07B |
| EPS (Diluted) | 4.06 | 4.15 | 2.75 | 5.06 | 5.32 |
| Gross Profit | 63.08B | 62.80B | 61.46B | 60.60B | 61.11B |
| Operating Income | 29.26B | 30.60B | 28.83B | 30.47B | 31.97B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 404.26B | 384.71B | 380.26B | 379.68B | 366.60B |
| Total Liabilities | 298.52B | 284.14B | 286.46B | 287.22B | 283.40B |
| Shareholders' Equity | 104.46B | 99.24B | 92.43B | 91.14B | 81.79B |
| Total Debt | 200.59B | 168.36B | 174.94B | 176.33B | 177.93B |
| Cash & Equivalents | 19.05B | 4.19B | 2.07B | 2.61B | 2.92B |
| Current Assets | 56.92B | 40.52B | 36.81B | 37.86B | 36.73B |
| Current Liabilities | 62.37B | 64.77B | 53.22B | 50.17B | 47.16B |